The interferon gene signature is increased in early treatment-naïve rheumatoid arthritis and predicts a poorer response to initial therapy

Publication date: Available online 5 October 2017
Source:Journal of Allergy and Clinical Immunology
Author(s): Faye AH. Cooles, Amy E. Anderson, Dennis W. Lendrem, Julie Norris, Arthur G. Pratt, Catharien Hilkens, John D. Isaacs

Teaser

The interferon gene signature in early, disease modifying drug naïve rheumatoid arthritis predicts clinical outcomes at 6 months after therapy initiation. We suggest type 1 interferons may be a future therapeutic target in early RA.


http://ift.tt/2x27sjH